EUVIMEDEUVIMED entdecken
Crossref

Ripretinib inhibits polyclonal drug-resistant KIT oncoproteins: the next step forward in gastrointestinal stromal tumor therapy

Maria Debiec-Rychter, Piotr Rutkowski

Gastrointestinal Stromal Tumor · 2023

DOI: 10.21037/gist-22-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastrointestinal Stromal Tumor, 2023. Verfasst von Maria Debiec-Rychter und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Debiec-Rychter, M., & Rutkowski, P. (2023). Ripretinib inhibits polyclonal drug-resistant KIT oncoproteins: the next step forward in gastrointestinal stromal tumor therapy. Gastrointestinal Stromal Tumor. https://doi.org/10.21037/gist-22-5

Vancouver

Debiec-Rychter M, Rutkowski P. Ripretinib inhibits polyclonal drug-resistant KIT oncoproteins: the next step forward in gastrointestinal stromal tumor therapy. Gastrointestinal Stromal Tumor. 2023. doi:10.21037/gist-22-5

BibTeX
@article{DebiecRychter2023,
  author = {Debiec-Rychter, Maria and Rutkowski, Piotr},
  title = {Ripretinib inhibits polyclonal drug-resistant KIT oncoproteins: the next step forward in gastrointestinal stromal tumor therapy},
  journal = {Gastrointestinal Stromal Tumor},
  year = {2023},
  doi = {10.21037/gist-22-5}
}
Kostenlos starten →